In this round of price revision/fixation, as many as nine drugs of Cadila Healthcare/Cadila Pharma companies are involved. The other companies whose formulation prices have been revised/fixed are Wyeth Lederle, Core Healthcare, Hoechst Marion Roussel, Merind, Ranbaxy and Morpen Lab.

Of the total of 17 formulation packs for which prices have been revised/fixed, prices of two packs have been revised downwards. Prices of the remaining formulations have been revised upwards. Manufacturers have been given a fortnight's time to adhere to the revised/fixed price structure from the date of the receipt of the NPPA order, the release adds.

The downward revision of twoformulation packs has brought down prices of Loridin-D (of Cadila) and Claridin-D (of Morpen) tablets between 12.88 per cent and 16.80 per cent. Upward revision of formulation pack prices have hiked the prices of as many as nine formulation packs between 1.33 per cent and 16.12 per cent.